Clinical trial
Optimal Dose of Prophylactic Naloxone in Reducing Opioid-Induced Side Effects in…
NCT00330343 · Johns Hopkins University, Other · Completed
Key facts
| NCT number | NCT00330343 |
|---|---|
| Title | Optimal Dose of Prophylactic Naloxone in Reducing Opioid-Induced Side Effects in Children/Adolescents |
| Official title | The Optimal Dose of Prophylactic Naloxone in Ameliorating Opioid Induced Side Effects in Children and Adolescents Receiving Intravenous Patient Controlled Analgesia (IVPCA) Morphine for Moderate to Severe Pain: A Pharmacodynamic, Pharmacokinetic, and Pharmacogenetic Study |
| Lead sponsor | Johns Hopkins University, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pain, Nausea, Pruritus |
| Intervention type | Drug |
| Interventions | naloxone |
| Enrollment | 75 |
| Start date | May 1, 2004 |
| Primary completion | Jun 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | May 26, 2006 |
| Last update posted | Jul 19, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: